AI Spatial Biomarkers & Diagnostics for Antibody-Drug Conjugates (ADCs)
The mechanism of action (MOA) of the next generation of protein-directed therapeutics are complex and require a new generation of biomarker assays that accurately reflect this complexity. Antibody-drug conjugates (ADCs), multi-specifics, and immunotherapy combos increasingly depend on spatial scoring and multiplex detection to predict treatment outcomes.
GenomeWeb: Spatial AI Biomarkers: Expending The Eligible Patient Pool with Novel Histopathology Signatures
In this webinar, Justin Lucas, head of translational research at Adlai Nortye, and Ken Bloom, head of pathology at Nucleai will share insights on how AI-driven spatial biomarker analysis can extract predictive signatures across multiple pathology modalities and spatial transcriptomics.
